KILL New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

 

Genentech requests that their press release NewsItemId: 20240125093104 “New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)” be killed.

The release was issued prematurely by Genentech.

A replacement release will be issued at a later date.

Contacts

Media Contact:

Shirley Dang, (650) 467-6800

Advocacy Contact:

Danielle Haney, (240) 805-4810

Investor Contacts:

Loren Kalm, (650) 225-3217

Bruno Eschli, +41 61 687 5284

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  274.48
+2.22 (0.82%)
AAPL  313.33
+0.92 (0.29%)
AMD  483.36
-5.92 (-1.21%)
BAC  63.17
+0.17 (0.27%)
GOOG  353.47
-3.15 (-0.88%)
META  592.10
+2.20 (0.37%)
MSFT  499.99
+0.13 (0.03%)
NVDA  223.96
+4.97 (2.27%)
ORCL  147.02
+3.55 (2.47%)
TSLA  328.58
+9.05 (2.83%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.